KR20090068376A - 염증 질환에서 4-1ｂｂ 리간드 - Google Patents

염증 질환에서 4-1ｂｂ 리간드 Download PDF

Info

Publication number
KR20090068376A
KR20090068376A KR1020097010071A KR20097010071A KR20090068376A KR 20090068376 A KR20090068376 A KR 20090068376A KR 1020097010071 A KR1020097010071 A KR 1020097010071A KR 20097010071 A KR20097010071 A KR 20097010071A KR 20090068376 A KR20090068376 A KR 20090068376A
Authority
KR
South Korea
Prior art keywords
1bbl
polypeptide
amino acid
blocker
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097010071A
Other languages
English (en)
Korean (ko)
Inventor
영 준 강
자화이 한
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20090068376A publication Critical patent/KR20090068376A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
KR1020097010071A 2006-10-16 2007-10-16 염증 질환에서 4-1ｂｂ 리간드 Withdrawn KR20090068376A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85202206P 2006-10-16 2006-10-16
US60/852,022 2006-10-16
US91756107P 2007-05-11 2007-05-11
US60/917,561 2007-05-11

Publications (1)

Publication Number Publication Date
KR20090068376A true KR20090068376A (ko) 2009-06-26

Family

ID=39364965

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010071A Withdrawn KR20090068376A (ko) 2006-10-16 2007-10-16 염증 질환에서 4-1ｂｂ 리간드

Country Status (11)

Country Link
US (1) US20100098689A1 (enExample)
EP (1) EP2097454A2 (enExample)
JP (1) JP2010506921A (enExample)
KR (1) KR20090068376A (enExample)
AU (1) AU2007318219A1 (enExample)
BR (1) BRPI0717744A2 (enExample)
CA (1) CA2666306A1 (enExample)
IL (1) IL197637A0 (enExample)
MX (1) MX2009004021A (enExample)
RU (1) RU2009110153A (enExample)
WO (1) WO2008057171A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248157A1 (en) * 2001-09-14 2004-12-09 Michal Ayalon-Soffer Novel polynucleotides encoding soluble polypeptides and methods using same

Also Published As

Publication number Publication date
JP2010506921A (ja) 2010-03-04
BRPI0717744A2 (pt) 2013-11-12
IL197637A0 (en) 2011-08-01
WO2008057171A2 (en) 2008-05-15
EP2097454A2 (en) 2009-09-09
CA2666306A1 (en) 2008-05-15
MX2009004021A (es) 2009-08-12
US20100098689A1 (en) 2010-04-22
WO2008057171A3 (en) 2008-11-20
AU2007318219A1 (en) 2008-05-15
RU2009110153A (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
Wang et al. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway
Kang et al. Cell surface 4-1BBL mediates sequential signaling pathways' downstream'of TLR and is required for sustained TNF production in macrophages
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
US20070087988A1 (en) Hematopoietic progenitor kinase 1 for modulation of an immune response
KR20180097645A (ko) 섬유증의 치료
US20080241130A1 (en) Methods and compositions for modulating il-17f/il-17a biological activity
US20100183633A1 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
CA2423052C (en) Screening assays for agonists or antagonists of receptor activator of nf-kb
JP2005532256A (ja) 慢性関節リウマチを治療するためのｌｉｒ機能の調節
JP2015173601A (ja) がん幹細胞の増殖抑制物質のスクリーニング方法
WO2007015587A1 (ja) アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法
JP6852926B2 (ja) 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
CN101528779A (zh) 炎症性疾病中的4-1bb配体
WO2005028664A2 (en) Modulation of programmed necrosis
US20110135574A1 (en) Methods of treating kidney disease
WO2003052121A2 (en) Method of reducing angiogenesis
US20100098689A1 (en) 4-1 bb ligand in inflammatory diseases
WO2011045352A2 (en) Spleen tyrosine kinase and brain cancers
EP2241323A1 (en) Tenascin-W and brain cancers
JP2009159869A (ja) 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
HK1134304A (en) 4-1 bb ligand in inflammatory diseases
WO2006068133A1 (ja) Ｎｆａｔ２発現抑制方法
US20070004657A1 (en) Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
US7432343B2 (en) Diagnostic application of mail

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid